NASDAQ:GRAL 3 October 2025 - 27 February 2026

GRAIL’s stock price exploded after the company announced a strategic alliance with Samsung on October 16. Under the deal, Samsung C&T will invest $110 million in GRAIL and become the exclusive distributor of the Galleri multi-cancer blood test in South Korea, with rights to expand into Japan and Singaporets2.tech. Samsung Electronics is also participating and plans to explore AI and health-data collaborations with GRAILts2.tech. This marks a major vote of confidence from one of Asia’s largest conglomerates. The partnership is expected to close by early 2026 and gives GRAIL a powerful commercialization partner in key Asian marketstradingview.com.

GRAIL’s shares surged after it announced a deal on Oct. 16 to partner with Samsung in Asia. The binding Letter of Intent involves Samsung C&T and Samsung Electronics investing $110 million in GRAIL at $70.05 per share, with Samsung C&T to distribute the Galleri multi-cancer screening test in South Koreainvesting.comprnewswire.com. This collaboration gives Samsung “a strong foothold for expanding into the cancer screening field”, according to Jaywoo Kim, EVP of Samsung C&Tprnewswire.com. GRAIL’s President of International Business, Sir Harpal Kumar, said the deal “strengthens our balance sheet and provides further cash runway” as the company advances toward test reimbursement globallyinvesting.comprnewswire.com. Under the LOI, definitive agreements are expected in early 2026, with testing operations to begin soon after closingprnewswire.cominvesting.com.